Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis. [electronic resource]
Producer: 20160526Description: 1840-2 p. digitalISSN:- 1468-3083
- Adjuvants, Immunologic -- administration & dosage
- Administration, Topical
- Aged
- Aminoquinolines -- administration & dosage
- Delayed-Action Preparations
- Dose-Response Relationship, Drug
- Double-Blind Method
- Face
- Female
- Follow-Up Studies
- Humans
- Imiquimod
- Keratosis, Actinic -- drug therapy
- Male
- Scalp
- Severity of Illness Index
- Skin -- metabolism
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.